Skip to main content

FLOVENT HFA

Generic: fluticasone propionate

Verified·Jun 8, 2026
Manufacturer
GlaxoSmithKline
NDC
50090-0910
RxCUI
895999
Route
RESPIRATORY (INHALATION)
ICD-10 indication
J45.909

Affordability Check

How much will you actually pay for FLOVENT HFA?

In 30 seconds, see every legitimate way to afford FLOVENT HFA — Medicare copay, manufacturer copay card, Patient Assistance Program, grants, or cash.

Check my options →

About FLOVENT HFA

What is this medication?

FLOVENT HFA is an inhaled corticosteroid medication used for the long-term maintenance treatment of asthma in adults and children. It contains the active ingredient fluticasone propionate, which works by reducing swelling and inflammation in the airways of the lungs. By decreasing this irritation over time, the medication helps to prevent common asthma symptoms such as wheezing, shortness of breath, and chest tightness.

This medication is intended for daily use to control chronic symptoms and should not be used as a rescue treatment for sudden asthma attacks. Because it focuses on long-term management, patients must use it regularly as prescribed by their doctor to see the full benefits. Consistent use helps to improve overall lung function and reduces the frequency of flare-ups, allowing individuals to better manage their respiratory health on a day-to-day basis.

Copay & patient assistance

  • Patient Copay Amount: At no cost for eligible patients through the Patient Assistance Program.
  • Maximum Annual Benefit Limit: Not Publicly Available.
  • Core Eligibility Restrictions: Patients must be US residents; eligibility varies by specific GSK product and is determined by the GSK Patient Access Programs Foundation.
  • RxBIN, PCN, and Group numbers: Not Publicly Available.

External links go directly to the manufacturer's portal. RxCopays does not receive compensation for referrals.

Compare pricing elsewhere

RxCopays doesn't sell drugs or take referral fees. Here are the transparent-pricing directories we recommend checking alongside your insurance formulary.

We deep-link because transparency helps patients. None of these partners pay RxCopays.

Prescribing information

From the FDA-approved label for FLOVENT HFA. Official source: DailyMed (NLM) · Label effective Feb 4, 2026

Indications and usage
Uses Temporarily relieves these symptoms of hay fever or other upper respiratory allergies: nasal congestion itchy, watery eyes itchy nose runny nose sneezing
Dosage and administration
Directions read the Quick Start Guide for how to: prime the bottle use the spray clean the spray nozzle shake gently before each use use this product only once a day do not use more than directed ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER Week 1- use 2 sprays in each nostril once daily Week 2 through 6 months- use 1 or 2 sprays in each nostril once daily, as needed to treat your symptoms After 6 months of daily use – ask your doctor if you can keep using CHILDREN 4 TO 11 YEARS OF AGE the growth rate of some children may be slower while using this product. Children should use for the shortest amount of time necessary to achieve symptom relief. Talk to your child’s doctor if your child needs to use the spray for longer than two months a year. an adult should supervise use use 1 spray in each nostril once daily CHILDREN UNDER 4 YEARS OF AGE do not use
Warnings
Warnings Only for use in the nose. Do not spray into your eyes or mouth.

Label text is reproduced as-is from the FDA-approved label. We do not paraphrase, summarize, or omit. Content above is for informational purposes only and is not medical advice. Always consult your prescribing clinician or pharmacist before making decisions about your medication.

Conditions we've indexed resources for

Click a condition to see copay cards, grants, and PA rules specific to it. For the full list of FDA-approved indications, see Prescribing information above.

Medicare Part D coverage

How FLOVENT HFA appears across Medicare Part D plan formularies nationally. Source: CMS monthly Prescription Drug Plan file (2026-04-30).

Covered by plans

13%

736 of 5,509 plans

Most common tier

Tier 4

On 33% of covering formularies

Prior authorization required

0%

of covering formularies

TierFormularies on this tierShare
Tier 1 (preferred generic)35
28%
Tier 2 (generic)30
24%
Tier 3 (preferred brand)18
15%
Tier 4 (non-preferred brand)41
33%

Step therapy: 20% of formularies

Quantity limits: 96% of formularies

Coverage breadth: 124 of 65 formularies

How to read this:plans on the same formulary share tier + PA rules. Your specific plan's copay depends on (a) the tier above, (b) your plan's cost-share for that tier, (c) whether you're in the initial coverage phase or past the 2026 $2,000 out-of-pocket cap. For your exact plan, check its Summary of Benefits or log in to your Medicare.gov account. Copay cards don't apply to Medicare (federal law).

Prior authorization & coverage

PayerPAStep therapyCopay tier

Medicare Part D

Related drugs

How this page is sourced

  • Drug identity verified against openFDA NDC Directory.
  • Label text (when shown) originates from NLM DailyMed.
  • Copay and assistance URLs verified periodically; if you hit a broken link, tell us.